CentoNIPT® – Non-Invasive Prenatal Testing at CENTOGENE
Get your results within 5 business days. CentoNIPT offers genetic, non-invasive prenatal testing (NIPT) to screen for the most common fetal chromosomal abnormalities. Our test combines the latest next generation sequencing technology with expert medical reporting.
*Note: CentoNIPT is unavailable in the US.
With CentoNIPT CENTOGENE Now Offers Non-Invasive Prenatal Testing That Provides a Fast and Accurate Screen for the Most Common Prenatal Chromosomal Abnormalities.*
CentoNIPT is performed on a single maternal blood sample and combines the latest next generation sequencing technology with the highest quality medical reporting. It provides unparalleled accuracy and detection compared to other non-invasive testing methods – ultrasonography or nuchal translucency testing.
Our medical expertise is ideally suited to provide you and your patients with reliable, well supported result interpretation.
Why Choose CentoNIPT?
100% safe
Only 9ml of maternal blood required
as early as possible
Test performed from the 10th gestational week
Fast & RELIABLE results
Highly accurate results available within 5 business days
Easy HAndling
CentoNIPT® kit free of charge. Return shipment via phone call
Illumina VeriSeq™ NIPT Solution v2
Expertise You Can Trust
Conventional prenatal testing for fetal chromosomal abnormality involves either chorionic villus sampling or amniocentesis. These procedures are highly invasive and carry an elevated risk of miscarriage, but despite this have become standard practice worldwide due to their high levels of accuracy and the range of abnormalities they can detect.
Approximately 1% of All Babies Will Be Born With a Chromosomal Abnormality
- Fetal chromosomal abnormalities are causing physical disability and/or mental retardation
- 70% of syndromic congenital abnormalities are contributed by Trisomy T21, T18 or T13 and 10% by Turner syndrome (Monosomy X)
- The risk of trisomy increases significantly with maternal age
Trisomies
| Trisomies | Sensitivity | Specificity |
|---|---|---|
| Trisomy 21 (Down syndrome) | >99.9% | 99.9% |
| Trisomy 18 (Edwards syndrome) | >99.9% | 99.9% |
| Trisomy 13 (Patau syndrome) | >99.9% | 99.9% |
Sex Chromosome Aneuploidies & Fetal Gender
| Sex Chromosome Aneuploidies | Concordance with cytogenetic results |
|---|---|
| XX | 100.0 % |
| XY | 100.0 % |
| X0 (Turner syndrome) | 90.5 % |
| XXX (Triple X syndrome) | 100.0 % |
| XXY (Klinefelter syndrome) | 100.0 % |
| XYY (Jacobs syndrome) | 91.7 % |
CentoNIPT Reporting Information
CentoNIPT is only designed to analyze chromosome aneuploidies of the fetus after 10 weeks of gestation. Reported are overrepresentations of chromosomes 21, 18 and 13, as well as the sex chromosome aneuploidies XO, XXX, XXY and XYY. This screening test does not test for aneuploidies in other chromosomes not mentioned above and can therefore not exclude abnormalities in these.
Chromosome aneuploidies for a twin gestation can in general be detected by this test. However, the test cannot be attributed to individual twin fetuses because in twin gestations sensitivity and specificity for detection of aneuploidies are limited. In case of twin pregnancy and detection of only one Y chromosome by the test, the fetal gender of each individual twin cannot be determined by the test.
CENTOGENE Reports NIPT Results As Follows:
High risk for aneuploidy – if CentoNIPT identifies an aneuploidy (chromosome 13,18 or 21 or gonosomal chromosomes), CENTOGENE reports high risk for aneuploidy and provides data on fetal DNA fraction in the sample of mother´s peripheral blood (in percentages) and the data on fetal gender if requested. We urgently recommend to the referring physician or the genetic counselor to determine and decide if further invasive testing and subsequent analysis is needed.
Low risk for aneuploidy – if CentoNIPT did not indicate a trisomy of chromosome 13, 18, or 21 or gonosomal abnormalities, CENTOGENE reports low risk for aneuploidy together with the data on fetal DNA fraction and the data on fetal gender if requested. A negative result cannot entirely exclude the possibility of fetoplacental mosaicism. Thus, CENTOGENE is giving negative results of NIPT together with the suggestion: if the fetus shows abnormalities on ultrasound investigation, or if a family history of fetal abnormalities or other genetic disorders exists, we urgently recommend to the referring physician or the genetic counselor to determine and decide if further invasive testing and subsequent analysis is needed.
In the very unlikely case of unclear results of the non-invasive prenatal testing due to the limitation of the system, we recommend further follow-up of the fetal growth using ultrasound as well as 2nd trimester screens. In case of any abnormalities observed on the ultrasound examination or if there is a positive family history of fetal abnormalities or other genetic disorders, we highly suggest invasive testing and subsequent analysis.
Notation
Sample Preparation and analysis software are CE-IVD marked
Noninvasive prenatal testing (NIPT) based on cell-free DNA analysis from maternal blood is a screening test; it is not diagnostic. Test results must not be used as the sole basis for diagnosis. Further confirmatory testing is necessary prior to making any irreversible pregnancy decision.
Resources
Quick Links
Downloads
Request Form – CentoNIPT
Non-invasive prenatal testing
CentoNIPT Brochure
Expertise you can trust
CentoNIPT – Sample Report, Positive
High risk for aneuploidy
Scientific Publications
Turning Rare Disease Networks into Knowledge
CENTOGENE’s well-recognized expertise in Gaucher disease (GD) has helped to establish a global network of physicians interested in and aware of this rare metabolic disorder. The fact that CENTOGENE […]
CentoNIPT Is the Earliest and Most Accurate Way To Detect Trisomy 21
Conventional Prenatal Screening Methods vs. CentoNIPT
How To Order CentoNIPT
Ordering
Do you already have a CentoNIPT box? Get it now
Preparation
Prepare the maternal sample.
Selecting
Select your test in CentoPortal by using the NI code on the streck tube provided.
Sending
Pack and ship the sample in your CentoNIPT box free of charge.
Quick Result
Sample processing and results within 5 business days.
Download
Download your report from CentoPortal®.
Frequently Asked Questions Non Invasive Prenatal Testing
This analysis is restricted to fetal cells from the placenta and not from the fetus itself. Fetoplacental mosaicism, a different chromosomal setup for placenta and fetus, is very rare but cannot be ruled out. Although sensitivity and specificity of NIPT are indeed high, it is necessary to confirm such results by additional method(s), such as echosonographic findings, maternal serum analysis; or perhaps amniocentesis for confirmation of a positive result.
Yes. The fetal fraction is included in the result.
Yes. However, the gender information will be provided only after 12 weeks of gestation, as regulated by German law, as the test is performed in Germany.
We report aneuploidy, the occurrence of additional chromosomes in the fetus. However, this analysis is restricted to those chromosomes where a living fetus could be born with abnormalities. These chromosomes include chromosome 13, 18, 21 and the sex chromosomes.
The analysis only reports if an additional chromosome has been identified
YES – the data indicate an extra copy of one chromosome. We urgently recommend to the referring physician or the genetic counselor to determine and decide if further invasive testing and subsequent analysis is needed.
NO – the data do not indicate any extra copy of the aforementioned chromosomes.
CentoNIPT® is based on the in vitro diagnostic test Illumina VeriSeq™ NIPT Solution v2. This noninvasive IVD test utilizes whole-genome sequencing on cell-fetal DNA (cfDNA) fragments derived from maternal peripheral whole blood samples. After whole genome sequencing and bioinformatics analysis, chromosome read numbers and fetal fraction are combined and thus translated into chromosome ploidy. Finally, the comparison of the tested chromosomes by this test (21, 18, 13, X and Y) with reference chromosomes enables the identification of aneuploidies, which are then reported.
Related Webinars
CentoGenome Webinar - ‘A Look Into the Power of Whole Genome Sequencing’
Throughout the webinar, Prof. Peter Bauer will provide you with an overview of Whole Genome Sequencing (WGS) and share insights from our latest study – unlocking the clinical utility of WGS.
CentoWebinar – 'Um olhar sobre o poder do sequenciamento completo do genoma'
Ao longo do webinar, nosso convidado Dr. Salmo Raskin, fornecerá uma visão geral do sequenciamento completo do genom (WGS) e compartilhará as percepções de nosso estudo mais recente - revelando […]
Genetik & Amyloidose: Polyneuropathie und Kardiomyopathie
Sehen Sie sich jetzt unser Webinar über die angeborene TTR Amyloidose an. Hierbei handelt es sich um eine autosomal-dominante Erbkrankheit, die durch Mutationen im TTR – Gen verursacht und häufig […]
Get in Touch With Our Customer Support
Our consultation service is available in several languages.
+49 (0) 381 80 113 - 416
Mon. – Fri. 7 a.m. – 6:30 p.m. CET
Sat. 8 a.m. – 12 p.m. CET